Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 450 Ocean Dr #1205, Juno Beach, FL 33408, USA
- Website
- aqualungtherapeutics.com
- Founded
- 2010
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Signablok, Inc. | Worcester, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Eldec Pharmaceuticals, Inc. | Durham, NC | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Akanocure Pharmaceuticals Inc. | West Lafayette, IN | — |
| Creative Biotherapeutics LLC | Gurnee, IL | — |
| Cytoagents Inc. | Pittsburgh, PA | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Aqualung Therapeutics, Corp is a minority-owned, for-profit corporate entity registered in SAM.gov, located in Juno Beach, Florida, with an active registration through May 2026. The company appears to be a biotechnology research organization focused on developing novel monoclonal antibody therapies targeting inflammatory and fibrotic disease pathways. While specific details about the company's full portfolio are not provided, their federal grant award history suggests a specialized focus on developing therapeutic interventions for complex respiratory and inflammatory conditions.
The company has secured multiple federal grants from prestigious national institutes, including the National Institute of Allergy and Infectious Diseases, National Heart Lung and Blood Institute, and National Institute of Diabetes and Digestive and Kidney Diseases. Their research has concentrated on developing a humanized monoclonal antibody (ALT-100) that targets the ENAMPT-TLR4 signaling pathway to address serious medical conditions such as idiopathic pulmonary fibrosis, acute respiratory distress syndrome (ARDS), inflammatory bowel disease, and pulmonary hypertension. In collaboration with Quell Pharma, they have been developing innovative therapeutic approaches like the tandem P-selectin glycoprotein ligand-1 immunoglobulin (TSGL-IG) to inhibit leukocyte adhesion and reduce systemic inflammation. Their grant-funded research involves preclinical studies using mouse and rat models to optimize dosing, evaluate efficacy, and assess potential therapeutic windows for their investigational treatments across multiple disease states.
Quick answers
Is Aqualung Therapeutics, Corp registered in SAM.gov?
Yes. Aqualung Therapeutics, Corp's SAM.gov registration is active through April 22, 2027.
What is Aqualung Therapeutics, Corp's CAGE code?
Aqualung Therapeutics, Corp's CAGE code is 80NH5, and its Unique Entity ID (UEI) is MKDKZ3ZZ99A2.
What is Aqualung Therapeutics, Corp's most recent federal award?
Aqualung Therapeutics, Corp's most recent federal grant award is Targeting enampt-TLR4 signaling with the novel ALT-100 MAB to slow IPF progression (R41HL180035), from National Heart Lung and Blood Institute (NIH), on September 20, 2025.
On GovTribe
See Aqualung Therapeutics, Corp's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors